Incannex complete successful pre-ind meeting with the fda for cannquit-o for treatment of opioid use disorder

Melbourne, australia and new york, may 07, 2024 (globe newswire) -- incannex healthcare inc. (nasdaq: ixhl), (incannex or the company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce the successful completion of a pre-ind (investigational new drug) meeting with the u.s. food and drug administration (fda) regarding the development of cannquit-o for treatment of opioid use disorder (oud).
IXHL Ratings Summary
IXHL Quant Ranking